Liam Ratcliffe
CIK 1547100 · last filed 2026-08-11
Liam Ratcliffe is a corporate insider who has filed 51 SEC Form 4 insider transactions across 12 companies since 2014. The most recent filing, for OKUR, was dated Aug 11, 2026. Across all open-market trades the lifetime net is −$6.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.4M across reported positions. 19 SEC filings were submitted jointly with Philippe O. Chambon.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.43M
12
51
-$6.25M
Filer Profile
40 WEST 57TH ST, 28TH FLOOR
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | — | $3.10 | — | $0 | 3 | 2026-08-11 |
| IRON | Director | — | $70.06 | — | $0 | 4 | 2026-06-23 |
| UPB | Director | — | $5.73 | — | $0 | 3 | 2026-06-11 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2024-06-28 |
| ARVN | Director | 421,935 | $8.45 | $3.57M | -$10.41M | 11 | 2022-06-21 |
| PASG | Director | 103,472 | $5.00 | $517.4K | $10.00M | 4 | 2021-05-28 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | 622,772 | — | — | $6.60M | 6 | 2019-06-18 |
| Aptinyx Inc. (APTX) Delisted | Director | 2,244,526 | $0.06 | $136.9K | $4.00M | 2 | 2019-04-02 |
| PDSB | Director | 1,182,434 | $0.29 | $348.7K | $0 | 1 | 2019-03-18 |
| EDGE | Director | — | $51.80 | — | $0 | 4 | 2018-08-15 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Director | 279,703 | $25.59 | $7.16M | $6.38M | 2 | 2018-05-21 |
| Aravive, Inc. (VSAR) Delisted | 10%+ Owner | 401,562 | — | — | -$22.81M | 1 | 2014-12-22 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-11 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2026-06-23 | IRON | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | UPB | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2026-04-01 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | IRON | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-10-15 | UPB | Grant (A) | — | $0 | EDGAR |
| 2024-06-28 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | IRON | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.